Dynamics of clinical manifestations of gonarthritis in overweight hypertensive women under the influence of complex therapy

Abstract

The aim of the work was to study the dynamics of clinical manifestations of gonarthritis in women with hypertension and overweight under the influence of complex therapy. Materials and methods. A two-stage study was conducted on the effectiveness of Rosuvastatin and Arginine in the complex therapy for patients with gonarthritis in combination with hypertension and excess body weight. At the first stage, on the basis of the inpatient Rheumatology Department, 198 women hospitalized in the period 2018–2020 were prospectively examined after receiving their informed consent. The follow-up study of the second stage (2019–2021) was carried out at the outpatient department. At the follow-up stage, 134 women were examined. Depending on the accompanying pathology, the patients were divided into three groups. Results. The use of the proposed treatment option in the complex treatment for selected contingent of patients contributed to a significant reduction in the proportion of patients with movement restriction in Group 2 and Group 3 by 62.21 % and 52.12 %, pain during active movements by 24.89 % and 52.12 % and swelling of the joints by 13.8% and 12.65 %, respectively; a decrease in IL-6 levels in Group 2 and Group 3 by 3.64 and 1.36 times, CRP by 1.97 and 1.12 times, and an increase in IL-10 by 3.57 and 1.62 times, respectively; improvements in WOMAC scores in all studied groups with a significant increase in Group 2 and Group 3. Conclusions. The combination of Rosuvastatin 20 mg per day for the 3-month course and Arginine 100 ml intravenously No. 10 with subsequent oral administration of 5 ml 4 times daily for 1 month has been found to increase the effectiveness of treatment for patients with gonarthritis combined with hypertension and overweight, reduce the intensity and duration of joint pain syndrome and significantly improve the functional capacity of joints.